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Abstract 
RNA interference induced by double-stranded, small interfering RNA (siRNA) molecules has 
attracted great attention as a naturally-occurring approach to silence gene expression with high 
specificity.  The Myocardin-Related Transcription Factor/Serum Response Factor (MRTF/SRF) 
pathway is a master regulator of cytoskeletal gene expression and thus represents a promising 
target to prevent fibrosis.  A major hurdle to implementing siRNA therapies is the method of 
delivery and we have thus optimised lipid-peptide-siRNA (LPR) nanoparticles containing MRTF-B 
siRNAs as a targeted approach to prevent conjunctival fibrosis.  We tested fifteen LPR nanoparticle 
formulations with different lipid compositions, surface charges and targeting or non-targeting 
peptides in human conjunctival fibroblasts.  In vitro, the LPR formulation of DOTMA/DOPE lipid 
with the targeting peptide Y (LYR) was the most efficient in MRTF-B gene silencing and non-
cytotoxic compared to the non-targeting formulation.  In vivo, subconjunctival administration of 
LYR nanoparticles containing MRTF-B siRNAs doubled bleb survival in a pre-clinical rabbit 
model of glaucoma filtration surgery.  Furthermore, MRTF-B LYR nanoparticles reduced the 
MRTF-B mRNA by 29.6% in rabbit conjunctival tissues, which led to significantly decreased 
conjunctival scarring with no adverse side effects.  LYR-mediated delivery of siRNA shows 
promising results to increase bleb survival and to prevent conjunctival fibrosis after glaucoma 
filtration surgery. 
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1. Introduction 
Glaucoma is the leading cause of irreversible blindness in the world, currently affecting 
over 60 million people worldwide, and estimated to rise to 76 million by 2020 and nearly 112 
million by 2040.1  Postoperative subconjunctival and episcleral fibrosis represent the critical 
determinant of the long-term surgical outcome and intraocular pressure after glaucoma filtration 
surgery (GFS).2  Mitomycin-C (MMC) is an antimetabolite drug that is used to modulate wound 
healing in glaucoma surgery, and acts by inhibiting DNA synthesis and causing widespread 
apoptosis.3  Serious vision-threatening side effects have been associated with the use of MMC, 
namely a 5% risk of hypotonous maculopathy,4 severe infection,5 corneal melting and perforation,6 
and scleral calcification.7  In addition, some patients still scar and fail surgery despite 
antimetabolite therapy.  There is thus a large unmet need for alternative agents with more targeted 
physiological effects and less cytotoxicity. 
Serum response factor (SRF) is a ubiquitous transcription factor and a master regulator of 
cytoskeletal gene expression,8,9 including many genes involved in fibrosis.10-12  The Myocardin-
Related Transcription Factor (MRTF) family is one of the principal families of signal-regulated 
SRF co-activators.9,13  The two MRTF family members, MRTF-A and MRTF-B, are regulated by 
cytoskeletal dynamics and respond to variations in the cellular concentration of G-actin, to which 
they bind through N-terminal RPEL motifs.14,15  The MRTF/SRF pathway plays a key role in 
myofibroblast activation and has been linked to ocular,16-19 vascular,10 skin11 and lung fibrosis.12 
Small interfering RNAs (siRNAs) are double-stranded RNA molecules 20-25 nucleotides 
long that regulate gene expression by degrading messenger RNA targets specifically, thereby 
leading to gene silencing.20  We have previously shown that cationic lipid (L)- peptide (P)- siRNA 
(R) nanocomplexes (LPR) represent an efficient delivery system for MRTF-B gene silencing in 
human conjunctival fibroblasts.18  The LPR formulation used in vitro may not be suitable for in 
vivo application as cationic nanocomplexes can display poor tissue penetration, cause non-specific 
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binding to cells, interact with serum proteins and lead to inflammation.  Unlike cationic 
nanocomplexes, anionic nanocomplexes are resistant to aggregation in the presence of serum21 and 
can achieve significant gene silencing in delivering siRNA.22  Cholesterol is a non-charged helper 
lipid that plays a role in many cellular membrane-related events, such as membrane fusion and 
endocytosis, and introducing cholesterol as a component of certain DNA/RNA carriers can increase 
their hydrophobic stability and improve transfection in vivo compared to carriers not containing 
cholesterol.23,24  PEGylation can also reduce aggregation due to binding of serum proteins and can 
increase the receptor-targeted specificity.  In the case of anionic nanocomplexes, PEGylation can 
further enhance the transfection efficiency in cells.21  We thus optimised LPR formulations by 
varying the lipid composition to confer different surface properties, including surface charge and 
PEGylation to enhance their in vivo biocompatibility.  We also evaluated the peptide targeting 
specificity in LPR nanocomplexes in transfections of human conjunctival fibroblasts.  Finally, we 
investigated the safety and efficacy of MRTF-B siRNA delivered by targeted LPR nanoparticles on 
bleb survival and conjunctival scarring in a pre-clinical rabbit model of GFS. 
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2. Results 
2.1. Development and biophysical characterisation of cationic and anionic nanoparticles 
We developed and characterised fifteen LPR formulations using three types of liposomes 
[DD (DOTMA/DOPE), DC (DOTMA/DOPE + cholesterol), DA (anionic DOPG/DOPE + PEG)], 
five types of peptides [targeting (Y, ME27, KG31, KG32), non-targeting (ME72)], and siRNA [R].  
LPRs containing DD had a mean size of 119.5 ± 7.3 (SEM) nm (Figure 1A).  Targeting DD/Y/R 
(108.3 ± 6.4 nm) and DD/ME27/R (89.9 ± 2.7 nm) nanoparticles were similar in size to the non-
targeting DD/ME72/R (99.7 ± 3.4 nm).  Targeting DD/KG31/R (163.1 ± 2.5 nm) and DD/KG32/R 
(136.6 ± 1.7 nm) nanoparticles were slightly larger in size.  LPRs containing anionic DOPG/DOPE 
+ PEG lipid (DA) had a mean size of 102.1 ± 2.4 nm and were similar in size to DD-containing 
LPRs.  However, LPRs containing DOTMA/DOPE + cholesterol lipid (DC) were significantly 
larger in size (234.7 ± 11.0 nm) than LPRs containing DD or DA. 
LPRs containing DD and DC were strongly cationic and had a mean charge of +51.5 ± 1.7 
(SEM) mV and + 63.7 ± 1.8 mV, respectively, whereas LPRs containing DA were anionic (-44.4 ± 
3.6 mV) (Figure 1B).  LPRs containing DD and DA nanoparticles also had relatively low 
polydispersity indices (PDI) of 0.37 ± 0.01 and 0.25 ± 0.02, respectively (Figure 1C).  However, 
DC-containing LPRs had a high PDI of 0.84 ± 0.05.  PDIs greater than 0.3 are indicative of 
multiple populations rather than the ideal monodisperse population.  All LPR nanoparticle 
formulations were spherical in morphology using negative-staining TEM (Figure 1D).  The bigger 
size of DC-containing LPRs compared to those containing DD or DA was also verified by TEM. 
 
2.2. Enhanced silencing effect in human conjunctival fibroblasts transfected with receptor-
targeted nanoparticles 
For LPRs containing DD, the silencing efficiency on the MRTF-B gene in human 
conjunctival fibroblasts was significantly increased with the use of targeting peptides (Y: 52.7%, p 
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= 0.002; ME27: 49.1%, p = 0.0006; KG31: 55.4%, p = 0.0002; KG32: 53.5%, p = 0.004) compared 
to the non-targeting peptide (ME72: 38.1%, p = 0.014) (Figure 2A).  Similarly, for LPRs 
containing DC, the silencing efficiency of the MRTF-B gene was also significantly higher with the 
use of targeting peptides (Y: 41.8%, p = 0.011; ME27: 52.1%, p = 0.022; KG31: 54.1%, p = 0.002; 
KG32: 45.1%, p = 0.0006) compared to the non-targeting peptide (ME72: 23.7%, p = 0.002) 
(Figure 2B).  There were statistically significant differences in the MRTF-B gene expression 
between the ME27 and ME72 peptide containing LPR formulations with DD (p = 0.020) (Figure 
2A) and with DC (p = 0.002) (Figure 2B).  ME72 contains a scrambled sequence of the ME27 
targeting ligand and this result thus supports the targeting effect of the ME27 peptide.  However, 
targeting and non-targeting DA-containing LPRs did not have any statistically significant effect on 
MRTF-B gene silencing in human conjunctival fibroblasts (Figure 2C). 
 
2.3. Receptor-targeted LYR nanoparticles display low cytotoxicity in human conjunctival 
fibroblasts 
For LPRs containing DD, none of the MRTF-B siRNA loaded nanoparticles were cytotoxic 
in human conjunctival fibroblasts compared to control nanoparticles or untreated cells (Figure 3A).  
There was a statistically significant decrease in cell viability for LPRs containing DC-peptide 
ME27-control siRNA (p = 0.007), DC-peptide ME72-control siRNA (p = 0.041), DC-peptide 
KG31-control siRNA (p = 0.001), and DC-peptide KG31-MRTF-B siRNA (p = 0.008) (Figure 3B). 
For LPRs containing DA, there was also no statistically significant decrease in cell viability 
in human conjunctival fibroblasts compared to untreated cells, except for DA-peptide ME27-
MRTFB siRNA (p = 0.004) (Figure 3C).  Our results show that the cationic LPR formulation of 
DOTMA/DOPE with the targeting peptide Y (LYR) was the most efficient in MRTF-B gene 
silencing (52.7 ± 2.7 %) and the least cytotoxic in human conjunctival fibroblasts, therefore, this 
formulation was used in all subsequent experiments. 
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2.4. Biophysical characterisation and silencing effect of LYR nanoparticles in rabbit 
conjunctival fibroblasts 
The LYR nanoparticles containing control and rabbit MRTF-B siRNAs had a mean size of 
128.8 ± 1.7 (SEM) nm and 134.9 ± 4.3 nm, respectively (Figure 4A).  The LYR nanoparticles 
containing control siRNA (35.0 ± 3.1 mV) and rabbit MRTF-B siRNA (48.7 ± 1.9 mV) were both 
strongly cationic (Figure 4B).  The PDIs were 0.36 ± 0.01 and 0.41 ± 0.01 for control LYR and 
rabbit MRTF-B LYR nanoparticles, respectively, indicating that the populations were not 
monodisperse.  MRTF-B LYR nanoparticles decreased MRTF-B gene expression in rabbit 
conjunctival fibroblasts by 41.5% (p = 0.018) compared to control LYR nanoparticles (Figure 4C).  
MRTF-B LYR nanoparticles also did not have any significant effect on cell viability in rabbit 
conjunctival fibroblasts compared to control LYR nanoparticles (p = 0.168) (Figure 4D). 
 
2.5. In vivo administration of LYR nanoparticles increases the long-term success of surgery in 
a rabbit model of glaucoma filtration surgery 
We used an established and clinically validated rabbit model of experimental GFS to 
investigate the effects of LYR nanoparticles containing MRTF-B siRNA on wound healing in the 
conjunctiva.25,26  Subconjunctival scarring after GFS is one of the most aggressive models of scar 
tissue formation, and failure of surgery is due to excessive scarring.  A bleb arises when a filtration 
cannula is inserted during the surgery and drains aqueous fluid from the anterior chamber of the 
eye to under the conjunctiva (Figure 5A).  The primary efficacy end-point was bleb survival as this 
is indicative of the long-term opening of the filtration pathway created during surgery.  Bleb failure 
was defined as the appearance of a flat, scarred and vascularised bleb associated with a deep 
anterior chamber.  We tested the LYR formulation in vivo as it was non-cytotoxic and the most 
efficient in terms of MRTF-B gene silencing in human conjunctival fibroblasts.  Bleb survival was 
doubled from 11.0 ± 0.6 (SEM) days for control LYR nanoparticles to 22.0 ± 2.1 days for MRTF-B 
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LYR nanoparticles (p = 0.005), and to 22.5 ± 1.3 days for mitomycin-C (p = 0.001) (Figures 5B 
and 5C). 
 
2.6. LYR nanoparticles decrease conjunctival scarring and do not cause any local or systemic 
side effects 
The MRTF-B LYR nanoparticles significantly decreased the scar tissue formation in the 
rabbit conjunctiva compared to control nanoparticles (Figure 6A).  Total cellularity also remained 
significantly increased in the control LYR nanoparticles group compared to the MRTF-B LYR 
nanoparticles (Figure 6B).  In addition, MRTF-B LYR nanoparticles decreased the expression of 
αSMA by cells, suggesting the presence of fewer myofibroblasts (Figure 6C).  Newly-laid 
extracellular matrix and collagen were present to a greater degree in the control LYR nanoparticles 
group compared to the MRTF-B LYR nanoparticles (Figure 6D). 
We further tested the silencing effect of MRTF-B LYR nanoparticles on MRTF-B gene 
expression in vivo in rabbit conjunctival tissues.  MRTF-B LYR nanoparticles decreased the 
MRTF-B gene expression by 29.6% in rabbit conjunctival tissues compared to control LYR 
nanoparticles (p = 0.046) (Figure 7A).  MRTF-B LYR nanoparticles also decreased the ACTA2 
gene expression in rabbit conjunctival tissues compared to control LYR nanoparticles, however this 
was not statistically significant (p = 0.535) (Figure 7B).  In addition, none of the rabbits showed 
any signs of ocular or systemic toxicity during the study. 
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3. Discussion 
This study demonstrates proof-of-concept that MRTF-B targeting by small interfering RNA 
is an effective application of genetic inhibition to prolong bleb survival and to prevent conjunctival 
fibrosis after experimental GFS.  Moreover, we have shown that the MRTF-B siRNA-loaded 
nanoparticles are safe to use in vivo in the conjunctiva and do not lead to any local or systemic 
adverse side effects.  Our previous studies have also shown that direct injection is an efficient route 
of administration of nanoparticles, for example direct injection into subcutaneous tumours27,28 and 
convection enhanced delivery through a cannula directly into the brain.21,29 
Potential advantages of nanoparticle-mediated siRNA therapy over drugs, such as MMC, 
include its cell specificity, potency and duration.30  There has been increasing interest in developing 
siRNA-based therapeutics in herpetic stromal keratitis,31 retinoblastoma,32 ocular inflammation,33 
non-arteritic anterior ischemic optic neuropathy,34 age-related macular degeneration35,36 and to 
lower the intraocular pressure in glaucoma.37  Other research groups are also developing different 
types of nanoparticles to modulate wound healing in the eye.38,39  Layer-by-layer nanoparticles 
(LbL-NPs) represent an efficient delivery vehicle for the siRNA silencing of secreted protein, 
acidic, and rich in cysteine (SPARC).38  Cationic nano-copolymers combined with IKKβ siRNA 
[CS-g-(PEI-b-mPEG)/ IKKβ-siRNA] also increased bleb survival and decreased subconjunctival 
scarring in a monkey model of GFS.39  There were no toxic side effects reported with the layer-by-
layer nanoparticles and cationic nano-copolymers. 
By designing a series of peptides, the goal was to understand how these different 
interactions affect gene delivery outcomes.  Peptide Y was identified by biopanning a phage 
peptide library and closely resembles part of a targeting protein expressed by the intracellular 
pathogen Legionella pneumophila.40,41  Although the identity of the receptor is still unknown, we 
have shown that peptide Y mediates the targeted delivery of siRNA in nanocomplexes to different 
tissues, including cells of neuronal origin,41,42 lung cells,22,28,43 primary vascular cells and rabbit 
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aorta.40,44  ME27 is a cleavable peptide that contains a tripeptide Arg-Gly-Asp (RGD) motif that 
targets integrins, particularly αvβ3, αvβ5, and α5β1, and these surface integrin receptors are 
abundantly expressed on human eye fibroblasts.45 
The targeting peptide KG31 consists of a hydrophobic Y and KG32 contains a cleavable Y.  
We have previously synthesized peptides containing hydrophobic amino acids as spacers between a 
K16 moiety and an integrin-targeting motif.  Our previous results had also shown that vectors 
containing peptides incorporating linkers that are partly hydrophobic demonstrated improved 
transfection properties, which is likely due to the improved accessibility of the integrin-binding 
motif.46  We also hypothesized that by adding the cleavable linker RVRR in KG32, as is the case in 
peptide ME27, that this would promote processing of peptide components of receptor-targeted 
nanocomplex formulations.  RVRR peptide motifs are cleavable by the endosomal enzymes furin 
and cathepsin B.47  We have previously shown in vitro that peptides with cleavable linkers 
displayed improved transfection efficiencies compared to their non-cleavable peptide homologs.47  
The reason might be because endosomal cleavage of the peptides can lead to disengagement of the 
nanoparticle from the receptor, allowing more efficient release of the particle from the endosomal 
membrane, or removal of a peptide layer may make the particle smaller and thus more readily 
transported through the cytoplasm and the nuclear envelope. 
In this study, cationic formulations using targeting peptides Y, ME27, KG31 and KG32 
produced higher transfection efficiencies in human conjunctival fibroblasts than their non-targeting 
counterparts containing peptide ME72, suggesting receptor-specific transfection.  Our previous 
study has also shown that receptor-targeted nanoparticles using peptides Y and ME27 achieved 
higher gene silencing efficiencies in transfecting conjunctival fibroblasts than nanoparticles with 
the non-targeting peptide K16 or with no peptides.18  Even though the new targeting peptides KG31 
and KG32 increased the transfection efficiency and MRTF-B gene silencing in human conjunctival 
fibroblasts compared to the non-targeting peptide, thereby supporting our above hypothesis, they 
however did not provide improved gene silencing over peptide Y. 
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Several studies have also reported a size-dependent cytotoxicity of nanoparticles.48-50  In 
our study, LPRs containing DOTMA/DOPE lipid (DD) were around 120 nm with relatively low 
polydispersity index (0.37) and had no significant effect on cell viability in human conjunctival 
fibroblasts.  On the other hand, LPRs containing DOTMA/DOPE + cholesterol lipid (DC) had 
significantly larger particle size (around 235 nm) and high polydispersity index (0.84), indicating a 
broad particle size distribution, and were cytotoxic to human conjunctival fibroblasts.  LPRs 
containing anionic DOPG/DOPE + PEG lipid (DA) were around 102 nm with low polydispersity 
index (0.25) and had no significant effect on cell viability.21,29 
Previous studies have shown increased targeted transfection efficiency, superior distribution 
and decreased inflammatory response of anionic PEGylated nanocomplexes in vivo compared to 
their homologous cationic formulations.21,22,29  However, our results show that anionic PEGylated 
formulations did not have any significant effect in vitro on MRTF-B gene silencing in human 
conjunctival fibroblasts.  One reason might be that the previous studies were conducted in cell lines 
as opposed to the primary human conjunctival fibroblasts used here.  Therefore, on the basis of the 
in vitro silencing results, we did not progress to in vivo studies with the anionic formulations that 
could have shown possibly better silencing than those in the tissue culture studies and more 
comparable to that of the cationic counterparts.  Future studies could involve the use of reduced 
PEGylation (e.g. 0.5%, 1%) to see whether that will enhance the silencing efficiency of anionic 
nanoparticles in human conjunctival fibroblasts. 
Due to the positive zeta potential of MRTF-B LYR nanoparticles, interaction with proteins 
and other components in vivo can lead to aggregation.  We did not observe any aggregation in vivo 
and we achieved a 29.6% MRTF-B gene silencing in rabbit conjunctival tissues after a single 
subconjunctival injection of MRTF-B LYR nanoparticles compared to control nanoparticles.  This 
level of silencing was associated with an increase in bleb survival and a decrease in conjunctival 
scarring in a rabbit model of experimental GFS.  MMC did not have any significant advantage over 
LYR nanoparticles.  MMC works as an anti-scarring drug by causing widespread apoptosis of 
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fibroblasts and is not known to have an effect on the MRTF-B gene.3  LYR design and dosage can 
also be further optimised and improved in future studies.  We have previously shown that a 70% 
MRTF-B gene silencing in human conjunctival fibroblasts after a single transfection treatment 
completely blocked matrix contraction in a 7-day collagen contraction assay.18 
One of the major challenges in developing novel anti-fibrotic drugs in GFS is to design 
long-acting drugs that would only need to be applied once at the time of surgery.51  Future work 
will focus on optimising the best concentration and timing of injections to achieve long-acting and 
sustained gene silencing to prevent conjunctival fibrosis.  For future clinical development, it will 
also be important to develop protocols for large-scale mixing of the lipid, peptide and siRNA 
components using Good Manufacturing Practice (GMP) materials and processes.52,53  Such 
methods include microfluidic mixing and more standard, in-line mixing methodologies as reported 
for lipid and nucleic acid formulations.54 
 
4. Conclusion 
In this study, we have shown that receptor-targeted liposome-peptide-siRNA nanoparticles 
represent a safe and efficient siRNA delivery system that could be used to prolong bleb survival 
and to prevent conjunctival fibrosis after glaucoma filtration surgery, by targeting the MRTF-B 
gene as well as other potential gene targets associated with fibrosis. 
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5. Materials and Methods 
Materials 
1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA), 1,2-dioleoyl-sn-glycero-
3-phosphoethanolamine (DOPE), 1,2-dioleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (DOPG), 
1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] 
(DPPE PEG2000) and cholesterol were purchased from Avanti Polar Lipids (Alabama, USA).  The 
structures of the lipids, peptides and siRNAs are shown in Table 1.  Peptides Y 
(K16GACYGLPHKFCG), ME27 (K16RVRRGACRGDCLG), ME72 (K16RVR GACRGECLG), 
KG31 (K16RXSXGACYGLPHKFCG, Hydrophobic Y, X = epsilon-aminohexanoic acid), and 
KG32 (K16RVRRGACYGLPHKFCG, Cleavable Y) were synthesized by ChinaPeptides 
(Shanghai, China) and AMS Biotechnology (Abingdon, UK).  The siRNAs used in this study were 
custom-synthesized and purchased from Dharmacon (UK).  The siRNAs were dissolved in sterile 
RNAse-free water at a concentration of 2.5 mg/ml. 
 
Liposome preparation 
Cationic liposomes made were: DOTMA: DOPE (DD) at 1:1 molar ratio and DOTMA: 
DOPE: Cholesterol (DC) at a molar ratio of 47.5: 47.5: 5 mol%.  Anionic liposomes made were 
DOPG: DOPE: DPPE-PEG2000 (DA) at a molar ratio of 49.5: 49.5: 1 mol%.  The lipids were 
dissolved in chloroform at 10 mg/ml and a lipid film was produced in a rotary evaporator by slowly 
evaporating the chloroform.  Lipids were rehydrated with sterile RNAse-free water while 
constantly rotated overnight, and then sonicated in a water bath to reduce their size. 
 
Cell culture 
Human conjunctival fibroblasts were grown from donor human conjunctiva and informed 
consent was obtained from all subjects.  Rabbit conjunctival fibroblasts were grown from New 
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Zealand white rabbit conjunctival tissues.  The fibroblasts were maintained in Dulbecco’s modified 
Eagle’s medium (DMEM, Invitrogen) with 10% fetal calf bovine serum (FBS), 100 U/ml 
penicillin, 100 mg/ml streptomycin, and 2 nM L-glutamine, in tissue culture incubators with 5% 
CO2 and 95% humidity.  Fibroblasts between passages 2-8 were used in the experiments.  All 
experimental protocols were approved by the London-Dulwich Research Ethics Committee (REC 
10/H0808/127) and the institutional approval committee at the University College London Institute 
of Ophthalmology. 
 
Nanoparticle formulation 
LPRs containing DOTMA/DOPE (DD) and LPRs containing DOTMA/DOPE + cholesterol 
(DC) were prepared at a weight ratio of 1 (liposome): 4 (peptide): 1 (siRNA), by first mixing the 
liposome with the peptide, followed by the addition of siRNA.  The mixture was incubated at room 
temperature (25°C) for one hour to allow complex formation.  OptiMEM (Life Technologies, UK) 
was then added to give a final siRNA concentration of 50 nM.  LPRs containing DOPG/DOPE + 
anionic PEG (DA) were prepared at a weight ratio of 19 (liposome): 2.7 (peptide): 1 (siRNA), by 
first mixing the peptide with the siRNA and incubating for 30 minutes at room temperature.  The 
liposome was then mixed with the peptide-siRNA and incubated for a further 30 minutes. 
 
Nanoparticle size and zeta potential 
Nanoparticle size and zeta potential were determined by dynamic light scattering (DLS) and 
laser Doppler anemometry, respectively, using a Nano ZS Zetasizer (Malvern Instruments, 
Malvern, UK) with the following specifications: automatic sampling time of 10 measurements/ 
sample, refractive index of 1.330, dielectric constant 78.5, viscosity 0.8872 cP, and temperature of 
25°C.  Zeta potential settings were calibrated against the standard (-68 ± 6.8 mV).  Triplicate 
measurements were performed for each sample and the results were analysed using the software 
provided by the manufacturer (DTS version 5.03). 
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Transmission Electron Microscopy (TEM) 
The nanoparticles were applied onto a 300-mesh copper grid coated with a Formvar/ carbon 
support film (Agar Scientific, Stansted, UK) and processed as previously described 21.  The 
samples were negatively stained with 1% uranyl acetate for 2-3 seconds, before blotting with filter 
paper and air-drying.  Imaging was performed with a Philips CM120 BioTwin Transmission 
Electron Microscope and operated at an accelerating voltage of 120 kV.  Images were captured 
using an AMT 5MP digital TEMcamera (Deben UK Limited, Suffolk, UK). 
 
In vitro transfection 
The human and rabbit conjunctival fibroblasts were seeded at 1 x 105 cells/ well in 6-well 
plates (Falcon, Fisher Scientific UK) and incubated for 24 hours before the nanocomplexes were 
added.  The cells were incubated with the nanocomplexes in OptiMEM for 4 hours at 37°C.  The 
medium containing the nanocomplexes was then replaced by fresh growth medium and the cells 
were incubated for a further 48 hours at 37°C. 
 
Real-Time Quantitative PCR 
The human and rabbit conjunctival fibroblasts were lysed for RNA extraction using the 
RNeasy mini kit (Qiagen, UK) according to the manufacturer’s instructions.  The rabbit 
conjunctival tissues were mechanically dispersed and RNA was also extracted using the RNeasy 
mini kit (Qiagen, UK).  RT-qPCR reactions were performed using a SensiFASTTM SYBR Hi-ROX 
One-Step master mix (Bioline, UK) on a CFX Real-Time PCR detection system (Bio-Rad, Hemel 
Hempstead, UK).  The qRT-PCR assay conditions were: stage 1, 45°C for 20 minutes; stage 2, 
95°C for 3 minutes; stage 3, 95°C for 10 seconds, then 60°C for 25 seconds; repeated 40 times.  
The human Taqman gene expression assays were MRTF-B/MKL2 (Hs00401867_m1) and GAPDH 
(Hs02758991_g1) (ThermoFisher Scientific, UK).  The rabbit primers were: MRTF-B, 5’-
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CTCCGATGTGGGTTTATGGGT-3’, 3’-GGAAGTGGCATCAGGACAGT-5’; ACTA2, 5’-
TCCACCGCAAATGCTTCTAAGT-3’, 3’-ATGAGTCAGAGCTTTGGATAGGC-5’; GAPDH, 
5’-CGAGACACGATGGTGAAGGT-3’, 3’-CCAGCATCACCCCACTTGAT-5’.  All mRNA 
values were normalized relative to that of GAPDH and triplicate experiments were performed for 
each condition. 
 
Cell proliferation assay 
The human and rabbit conjunctival fibroblasts were seeded at 0.625 x 104 cells/ well in 96-
well plates (Falcon, Fisher Scientific UK).  The cells were transfected with six replicates for each 
nanoparticle formulation and cell viability was measured using the Cell Titer 96 Aqueous one 
solution cell proliferation assay (Promega, UK).  The medium was replaced with 100 µl fresh 
growth medium per well and 20 µl of the Cell Titer 96 Aqueous one solution were added to each 
well.  The cells were incubated for 2 hours and absorbance at 540 nm was measured using a 
FLUOstar Optima (BMG LABTECH).  Cell viability for each formulation was expressed as a 
percentage of the viability of control cells. 
 
Rabbit glaucoma filtration surgery (GFS) model of scar tissue formation 
All animal procedures were performed in accordance with the Association of Research in 
Vision and Ophthalmology (ARVO) Statement for the Use of Animals in Ophthalmic and Vision 
Research, and all animal experimental protocols were approved by the Home Office UK (PPL 
70/8074).  Eighteen female New Zealand white rabbits (1.5-2 kg, 10-12 weeks, Envigo, UK) 
underwent experimental GFS to the left eye under general anaesthesia 25,26.  A superonasal fornix-
based conjunctival flap was raised behind the limbus and a micro-vitreoretinal blade (20 gauge, 
0.90 mm, Surgistar USA) was used to make a partial thickness scleral tunnel to the corneal stroma.  
A 22 gauge, 25 mm intravenous cannula was passed through the tunnel and the needle was 
removed once it was visible in the cornea.  The cannula was advanced into the mid-pupillary area, 
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trimmed at its scleral edge and fixed to the scleral surface using a 10-0 nylon suture (Alcon, USA).  
The conjunctival incision was closed using two interrupted 10-0 nylon sutures.  In a randomised, 
prospective, single-masked observer study, the rabbits received intraoperative 0.2 mg/ml 
mitomycin-C [N=6] or a postoperative subconjunctival injection of 25 µg in 100 µl of MRTF-B 
LYR nanoparticles [N=6] or control LYR nanoparticles [N=6]. 
 
Post-operative clinical examination 
The animals were examined every 3 days by a single-masked blinded researcher.  Bleb 
width and length were measured using calipers and intraocular pressures were measured using a 
tonovet (Icare, UK).  The primary efficacy end-point was bleb survival as this is indicative of the 
long-term patency of the filtration pathway created during surgery.  Bleb failure was defined as the 
appearance of a flat, scarred, and vascularised bleb associated with a deep anterior chamber.  All 
animals were also evaluated for signs of local or systemic toxicity during the study. 
 
Histologic analysis 
The animals were sacrificed on day 30 and both eyes were enucleated.  The eyes were fixed 
in formalin, embedded in paraffin, and sequential 4 µm tissue sections were cut.  The sections were 
stained with hematoxylin and eosin (for cellularity and inflammatory cells), Gomori’s trichrome 
(for collagen), picrosirius red (for degree of fibrosis), and alpha-smooth muscle actin (αSMA) 
using a primary monoclonal mouse anti-human αSMA antibody (Clone 1A4; Dako, High 
Wycombe, UK) and a biotinylated secondary antibody (rabbit anti-mouse; Dako).  All the left 
operated eyes were compared to the right non-operated eyes that were used as controls for normal 
conjunctival tissue. 
 
Statistical analysis 
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All graphs display mean and standard error of the mean (SEM).  Statistical analysis was 
performed using the Student’s t-test to calculate statistically significant differences and p values.  
Survival analysis for bleb was performed using the Kaplan-Meier log rank test.  Statistically 
significant differences were expressed as *, p < 0.05; **, p < 0.01; ***, p < 0.001. 
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Figure Legends 
Figure 1. Biophysical characterisation of multiple lipid-peptide-human siRNA nanoparticle 
formulations. (A) Size in nm. (B) Zeta potential in mV. (C) Polydispersity index. Results represent 
mean ± SEM. (D) Negative staining transmission electron microscopy. Scale bar = 200 nm. DD, 
DOTMA/DOPE; DC, DOTMA/DOPE + cholesterol; DA, anionic DOPG/DOPE + PEG; Targeting 
peptides Y, ME27, KG31, KG32; Non-targeting peptide ME72; R, siRNA. 
 
Figure 2. In vitro transfections of human conjunctival fibroblasts and MRTF-B gene silencing by 
lipid-peptide-siRNA (LPR) nanoparticles. (A) LPRs containing DOTMA/DOPE lipid (DD). (B) 
LPRs containing DOTMA/DOPE + cholesterol lipid (DC). (C) LPRs containing anionic 
DOPG/DOPE + PEG lipid (DA). mRNA levels were normalized relative to that of GAPDH and the 
results represent mean ± SEM for triplicate experiments. *, p < 0.05; **, p < 0.01; ***, p < 0.001. 
 
Figure 3. Viability of human conjunctival fibroblasts after transfection with lipid-peptide-siRNA 
(LPR) nanoparticles for 48 hours. (A) LPRs containing DOTMA/DOPE lipid (DD). (B) LPRs 
containing DOTMA/DOPE + cholesterol lipid (DC). (C) LPRs containing anionic DOPG/DOPE + 
PEG lipid (DA). Results represent mean ± SEM for six independent replicates. *, p < 0.05; **, p < 
0.01. 
 
Figure 4. In vitro transfections of rabbit conjunctival fibroblasts using LPR formulations of 
DOTMA/DOPE with the targeting peptide Y and rabbit siRNA sequences (LYR). (A) Size in nm. 
(B) Zeta potential in mV. Results represent mean ± SEM. (C) mRNA levels were normalized 
relative to that of GAPDH and the results represent mean ± SEM for triplicate experiments. *, p < 
0.05. (D) Cell viability after transfection for 48 hours. Results represent mean ± SEM for six 
independent replicates. 
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Figure 5. Effect of LYR nanoparticle formulations on a rabbit model of glaucoma filtration 
surgery. (A) Schematic diagram to illustrate aqueous fluid draining through inserted filtration 
cannula and subconjunctival administration of nanocomplexes. (B) Morphology of blebs after 
surgery and treatment with MRTF-B LYR nanoparticles, control nanoparticles, or mitomycin-C 
(MMC). Arrows indicate bleb edges. (C) Kaplan-Meier graph comparing the bleb survival between 
MRTF-B LYR nanoparticles [N=6], control LYR nanoparticles [N=6], and MMC [N=6]. 
 
Figure 6. Histology of rabbit conjunctival tissues. The left operated eyes were compared to the 
right non-operated eyes that were used as controls for normal conjunctival tissue. Scale bar = 100 
µm; c, conjunctiva, b, subconjunctival space, s, sclera. (A) Picrosirius red; (B) H&E; (C) αSMA; 
(D) Gomori’s trichrome stain. 
 
Figure 7. Gene silencing of (A) MRTF-B and (B) ACTA2 in rabbit conjunctival tissues after 
subconjunctival injection of MRTF-B LYR nanoparticles. mRNA levels were normalized relative 
to that of GAPDH and the results represent mean ± SEM for triplicate experiments. *, p < 0.05. 
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Table Legends 
Table 1. Structures of the different lipids and sequences of peptides and siRNAs 
Function Lipids Structure 
Cationic Lipid 
Structure 
DOTMA 
[1,2-di-O-octadecenyl-
3-trimethylammonium 
propane] 
 
 
Helper Lipid DOPE 
[1,2-dioleoyl-sn-
glycero-3-
phosphoethanolamine] 
 
Helper Lipid Cholesterol 
 
Anionic Lipid 
Structure 
DOPG 
[1,2-dioleoyl-sn-
glycero-3-phospho-(1'-
rac-glycerol)] 
 
 
 
 
Function Peptides Sequence 
Targeting Y K16GACYGLPHKFCG 
Targeting ME27 K16RVRRGACRGDCLG 
Non-Targeting ME72 K16RVRRGACRGECLG 
Targeting KG31 K16RXSXGACYGLPHKFCG 
(Hydrophobic Y), where X = epsilon-
aminohexanoic acid 
Targeting KG32 K16RVRRGACYGLPHKFCG (Cleavable 
Y) 
Function siRNAs Sequence 
Targeting MRTF-B (Human) GGAUGGAACUUUACCCUCA 
Targeting MRTF-B (Rabbit) CGAGAAAGGUGUUCACAAAUU 
Non-Targeting Control UGGUUUACAUGUCGACUAA 
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RNA interference induced by double-stranded, small interfering RNA (siRNA) is a naturally-
occurring approach to silence gene expression with high specificity. Yu-Wai-Man and 
colleagues show that lipid-peptide-siRNA (LPR) nanoparticles significantly increase bleb 
survival and prevent conjunctival fibrosis in a pre-clinical model of glaucoma filtration surgery. 
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